Q3 2025 Management View Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Dec 2 (Reuters) - Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine could be approved for emergency use within 24 to 72 hours after the U.S. health regulator's advisory committee meeting, Chief ...

Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide ...

Moderna's CEO says that people will likely need a fourth dose of a COVID-19 vaccine later this year. According to The Washington Post and CNBC, Moderna CEO Stéphane Bancel said at a conference hosted ...

Moderna announced the Food and Drug Administration has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 ...

Moderna is working on a stronger tool to fight the COVID-19 pandemic. However, officials say it will take time. The drugmaker says research is underway toward a one-dose, yearly booster to battle the ...

CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...

When Moderna CEO Stéphane Bancel addressed the J.P. Morgan Healthcare Conference in January 2021 — virtually, along with the rest of the participants who tuned in at the height of the Covid-19 ...